- A novel monoclonal antibody induces cancer cell apoptosis and enhances the activity of chemotherapeutic drugs.
A novel monoclonal antibody induces cancer cell apoptosis and enhances the activity of chemotherapeutic drugs.
Asian Pacific journal of cancer prevention : APJCP (2014-06-28)
Heng Xu, Yan-Na Tian, Bo-Ying Dun, Hai-Tao Liu, Guang-Kuo Dong, Jin-Hua Wang, Shang-Su Lu, Bo Chen, Jin-Xiong She
PMID24969863
ABSTRACT
A novel monoclonal antibody (mAb), known as AC10364, was identified from an antibody library generated by immunization of mice with human carcinoma cells. The mAb recognized proteins in lysates from multiple carcinoma cell lines. Cell cytotoxicity assays showed that AC10364 significantly inhibited cell growth and induced apoptosis in multiple carcinoma cell lines, including Bel/fu, KATO-III and A2780. Compared with mAb AC10364 or chemotherapeutic drugs alone, the combination of mAb AC10364 with chemotherapeutic drugs demonstrated enhanced growth inhibitory effects on carcinoma cells. These results suggest that mAb AC10364 is a promising candidate for cancer therapy.
MATERIALS
Product Number
Brand
Product Description
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-Lysine monohydrochloride, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Supelco
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-Lysine monohydrochloride, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland